Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2019

01-04-2019 | Hepatocellular Carcinoma | Review

Current State of Tumor Ablation Therapies

Authors: Christopher W. Bailey, Malcolm K. Sydnor Jr.

Published in: Digestive Diseases and Sciences | Issue 4/2019

Login to get access

Abstract

The most common primary liver malignancy, hepatocellular carcinoma (HCC), has a high likelihood of mortality, and much effort into early detection and treatment has occurred. Multiple staging systems have surfaced of which some guide treatment. Curative intent is a goal of early-staged HCC treatment, and this can be achieved with surgical resection, liver transplantation, and minimally invasive percutaneous therapies such as tumor ablation. Many of the newer ablation techniques have evolved from shortcomings of prior methods which have resulted in an expanded number of applications for tumor ablation. Our review focuses on current mainstream image-guided percutaneous ablation modalities which are commonly performed as an alternative to surgery.
Literature
1.
go back to reference Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from, to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 1990;2017:1683–1691. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from, to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 1990;2017:1683–1691.
2.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed
3.
go back to reference Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma; The BCLC staging classification. Semin Liver Dis. 1999;19:329–338.CrossRefPubMed Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma; The BCLC staging classification. Semin Liver Dis. 1999;19:329–338.CrossRefPubMed
4.
go back to reference Forner A, Reig M, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.CrossRefPubMed Forner A, Reig M, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.CrossRefPubMed
5.
go back to reference Habib A, Desai K, Hickey R, et al. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis. 2015;19:401–420.CrossRefPubMed Habib A, Desai K, Hickey R, et al. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis. 2015;19:401–420.CrossRefPubMed
6.
go back to reference Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.CrossRef Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.CrossRef
8.
go back to reference Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: A study on 207 patients. Cancer. 1992;69:925–929.CrossRefPubMed Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: A study on 207 patients. Cancer. 1992;69:925–929.CrossRefPubMed
9.
go back to reference Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.CrossRefPubMed Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.CrossRefPubMed
10.
go back to reference Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics. 2000;20:9–27.CrossRefPubMed Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics. 2000;20:9–27.CrossRefPubMed
11.
go back to reference Lencioni R, Crocetti L, Della Pina C, Cioni D. Image-Guided Ablation of Hepatocellular Carcinoma. In: Geschwind JFH, Soulen MC, eds. Interventional Oncology, Principle and Practice. New York, NY: Cambridge University Press; 2008:145–159.CrossRef Lencioni R, Crocetti L, Della Pina C, Cioni D. Image-Guided Ablation of Hepatocellular Carcinoma. In: Geschwind JFH, Soulen MC, eds. Interventional Oncology, Principle and Practice. New York, NY: Cambridge University Press; 2008:145–159.CrossRef
12.
go back to reference Koda M, Murawaki Y, Mitsuda A, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 2000;88:529–537.CrossRefPubMed Koda M, Murawaki Y, Mitsuda A, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 2000;88:529–537.CrossRefPubMed
13.
go back to reference Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients. Cancer. 1995;76:1737–1746.CrossRefPubMed Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients. Cancer. 1995;76:1737–1746.CrossRefPubMed
14.
go back to reference McWilliams JP, Yamamoto S, Raman SS, et al. Percutaneous ablation of hepatocellular carcinoma: Current status. J Vasc Interv Radiol. 2010;21:S204–S213.CrossRefPubMed McWilliams JP, Yamamoto S, Raman SS, et al. Percutaneous ablation of hepatocellular carcinoma: Current status. J Vasc Interv Radiol. 2010;21:S204–S213.CrossRefPubMed
15.
go back to reference Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240.CrossRefPubMed Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240.CrossRefPubMed
16.
go back to reference McGahan J, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol. 1990;25:267–270.CrossRefPubMed McGahan J, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol. 1990;25:267–270.CrossRefPubMed
17.
go back to reference Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol. 2000;174:323–331.CrossRef Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol. 2000;174:323–331.CrossRef
18.
go back to reference Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology. 2000;217:633–646.CrossRefPubMed Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology. 2000;217:633–646.CrossRefPubMed
19.
go back to reference Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–1937.CrossRefPubMed Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–1937.CrossRefPubMed
20.
go back to reference Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci. 2008;5:327–332.CrossRefPubMedPubMedCentral Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci. 2008;5:327–332.CrossRefPubMedPubMedCentral
21.
go back to reference Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg. 2010;252:903–912.CrossRefPubMed Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg. 2010;252:903–912.CrossRefPubMed
22.
go back to reference Lee HW, Lee JM, Yoon JH, et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 2018;94:74–82.CrossRefPubMedPubMedCentral Lee HW, Lee JM, Yoon JH, et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 2018;94:74–82.CrossRefPubMedPubMedCentral
23.
go back to reference Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193–200.CrossRefPubMed Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193–200.CrossRefPubMed
24.
go back to reference Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology. 2000;214:761–768.CrossRefPubMed Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology. 2000;214:761–768.CrossRefPubMed
25.
26.
go back to reference Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Intervent Radiol. 2000;11:1069–1075.CrossRef Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Intervent Radiol. 2000;11:1069–1075.CrossRef
27.
go back to reference Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buckowski AK. Radiofrequency ablation of porcine liver in vivo effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227:559–565.CrossRefPubMedPubMedCentral Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buckowski AK. Radiofrequency ablation of porcine liver in vivo effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227:559–565.CrossRefPubMedPubMedCentral
28.
go back to reference Bhardwaj N, Strickland AD, Ahmad F, Ataneysan L, West K, Lloyd DM. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology. 2009;41:168–172.CrossRefPubMed Bhardwaj N, Strickland AD, Ahmad F, Ataneysan L, West K, Lloyd DM. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology. 2009;41:168–172.CrossRefPubMed
29.
go back to reference Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–139.CrossRef Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–139.CrossRef
30.
go back to reference Tabuse K. A new operative procedure of hepatic surgery using a microwave tissue coagulator. Arch Jap Chir. 1979;48:160–172. Tabuse K. A new operative procedure of hepatic surgery using a microwave tissue coagulator. Arch Jap Chir. 1979;48:160–172.
31.
go back to reference Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K. Treatment of hepatocellular carcinoma: Value of percutaneous microwave coagulation. Am J Roentgenol. 1995;164:1159–1164.CrossRef Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K. Treatment of hepatocellular carcinoma: Value of percutaneous microwave coagulation. Am J Roentgenol. 1995;164:1159–1164.CrossRef
32.
go back to reference Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: Principles and applications. RadioGraphics. 2005;25:S69–S83.CrossRefPubMed Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: Principles and applications. RadioGraphics. 2005;25:S69–S83.CrossRefPubMed
33.
go back to reference Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver ablation: Best practice. Radiol Clin N Am. 2015;53:933–971.CrossRefPubMed Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver ablation: Best practice. Radiol Clin N Am. 2015;53:933–971.CrossRefPubMed
34.
go back to reference Wright SW, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–283.CrossRefPubMed Wright SW, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–283.CrossRefPubMed
35.
go back to reference Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma long-term outcome and prognostic factors. Cancer. 2009;115:1914–1923.CrossRefPubMed Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma long-term outcome and prognostic factors. Cancer. 2009;115:1914–1923.CrossRefPubMed
36.
go back to reference Llang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.CrossRef Llang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.CrossRef
37.
go back to reference Dong B, Liang P, Yu X, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: Results in 234 patients. Am J Roentgenol. 2003;180:1547–1555.CrossRef Dong B, Liang P, Yu X, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: Results in 234 patients. Am J Roentgenol. 2003;180:1547–1555.CrossRef
38.
go back to reference Xu L-F, Sun H-L, Chen Y-T, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456–463.CrossRefPubMed Xu L-F, Sun H-L, Chen Y-T, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456–463.CrossRefPubMed
39.
go back to reference Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:219–224.CrossRefPubMedPubMedCentral Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:219–224.CrossRefPubMedPubMedCentral
40.
go back to reference Cooper IS. Cryogenic surgery. A new method of destruction or extirpation of benign or malignant tissues. N Engl J Med. 1963;268:743–749.CrossRef Cooper IS. Cryogenic surgery. A new method of destruction or extirpation of benign or malignant tissues. N Engl J Med. 1963;268:743–749.CrossRef
41.
go back to reference Ravikumar TS, Kane R, Cady B, Jenkins R, Clouse M, Steele G Jr. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg. 1991;126:1520–1524.CrossRefPubMed Ravikumar TS, Kane R, Cady B, Jenkins R, Clouse M, Steele G Jr. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg. 1991;126:1520–1524.CrossRefPubMed
42.
go back to reference Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–369.CrossRef Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–369.CrossRef
43.
44.
go back to reference Permpongkosol S, Sulman A, Solomon SB, Gong GX, Kavoussi LR. Percutaneous computerized tomography guided renal cryoablation using local anesthesia: Pain assessment. J Urol. 2006;176:915–918.CrossRefPubMed Permpongkosol S, Sulman A, Solomon SB, Gong GX, Kavoussi LR. Percutaneous computerized tomography guided renal cryoablation using local anesthesia: Pain assessment. J Urol. 2006;176:915–918.CrossRefPubMed
45.
go back to reference Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB. Pain control requirements for percutaneous ablation of renal tumors: Cryoablation versus radiofrequency ablation—initial observations. Radiology. 2005;237:366–370.CrossRefPubMed Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB. Pain control requirements for percutaneous ablation of renal tumors: Cryoablation versus radiofrequency ablation—initial observations. Radiology. 2005;237:366–370.CrossRefPubMed
46.
go back to reference Gilbert JC, Onik GM, Hoddick WK, et al. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology. 1985;22:319–330.CrossRefPubMed Gilbert JC, Onik GM, Hoddick WK, et al. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology. 1985;22:319–330.CrossRefPubMed
47.
go back to reference Lee FT Jr, Chosy SG, Littrup PJ, Warner TF, Kuhlman JE, Mahvi DM. CT-monitored percutaneous cryoablation in a pig liver model: Pilot study. Radiology. 1999;211:687–692.CrossRefPubMed Lee FT Jr, Chosy SG, Littrup PJ, Warner TF, Kuhlman JE, Mahvi DM. CT-monitored percutaneous cryoablation in a pig liver model: Pilot study. Radiology. 1999;211:687–692.CrossRefPubMed
48.
go back to reference Silverman SG, Sun MR, Tuncali K, et al. Three-dimensional assessment of MRI-guided percutaneous cryotherapy of liver metastases. Am J Roentgenol. 2004;183:707–712.CrossRef Silverman SG, Sun MR, Tuncali K, et al. Three-dimensional assessment of MRI-guided percutaneous cryotherapy of liver metastases. Am J Roentgenol. 2004;183:707–712.CrossRef
49.
go back to reference Weber SM, Lee FT Jr, Warner TF, Chosy SG, Mahvi DM. Hepatic cryoablation: US monitoring of extent of necrosis in normal pig liver. Radiology. 1998;207:73–77.CrossRefPubMed Weber SM, Lee FT Jr, Warner TF, Chosy SG, Mahvi DM. Hepatic cryoablation: US monitoring of extent of necrosis in normal pig liver. Radiology. 1998;207:73–77.CrossRefPubMed
50.
go back to reference Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999;23:109–114.CrossRefPubMed Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999;23:109–114.CrossRefPubMed
51.
go back to reference Xu K-C, Niu L-Z, Zhou Q, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009;15:3664–3669.CrossRefPubMedPubMedCentral Xu K-C, Niu L-Z, Zhou Q, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009;15:3664–3669.CrossRefPubMedPubMedCentral
52.
go back to reference Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–231.CrossRefPubMed Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–231.CrossRefPubMed
53.
go back to reference Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: Irreversible electroporation. Radiology. 2010;255:426–433.CrossRefPubMed Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: Irreversible electroporation. Radiology. 2010;255:426–433.CrossRefPubMed
54.
go back to reference Seror O. Ablative therapies: Advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient? Diagn Interv Imaging. 2015;96:617–624.CrossRefPubMed Seror O. Ablative therapies: Advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient? Diagn Interv Imaging. 2015;96:617–624.CrossRefPubMed
55.
go back to reference Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Inter Radiol. 2014;25:112–118.CrossRef Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Inter Radiol. 2014;25:112–118.CrossRef
56.
go back to reference Sutter O, Calvo J, N’Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: A retrospective single-center case series. Radiology. 2017;284:877–886.CrossRefPubMed Sutter O, Calvo J, N’Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: A retrospective single-center case series. Radiology. 2017;284:877–886.CrossRefPubMed
57.
go back to reference Cornelis FH, Durack JC, Kimm SY, et al. A comparative study of ablation boundary sharpness after percutaneous radiofrequency, cryo-, microwave, and irreversible electroporation ablation in normal swine liver and kidneys. Cardiovasc Intervent Radiol. 2017;40:1600–1608.CrossRefPubMedPubMedCentral Cornelis FH, Durack JC, Kimm SY, et al. A comparative study of ablation boundary sharpness after percutaneous radiofrequency, cryo-, microwave, and irreversible electroporation ablation in normal swine liver and kidneys. Cardiovasc Intervent Radiol. 2017;40:1600–1608.CrossRefPubMedPubMedCentral
58.
go back to reference Niessen C, Beyer LP, Pregler B, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: A prospective safety and midterm efficacy study in 34 patients. J Vasc Inter Radiol. 2016;27:480–486.CrossRef Niessen C, Beyer LP, Pregler B, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: A prospective safety and midterm efficacy study in 34 patients. J Vasc Inter Radiol. 2016;27:480–486.CrossRef
59.
go back to reference Niessen C, Thumann S, Beyer L, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:1–8.CrossRef Niessen C, Thumann S, Beyer L, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:1–8.CrossRef
Metadata
Title
Current State of Tumor Ablation Therapies
Authors
Christopher W. Bailey
Malcolm K. Sydnor Jr.
Publication date
01-04-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05514-9

Other articles of this Issue 4/2019

Digestive Diseases and Sciences 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.